my country's recombinant protein new coronavirus vaccine clinical trial results released

Xinhua News Agency, Beijing, March 26 (Reporters Ruifeng Dong and Haitao Xu) China has approved a recombinant protein subunit new coronavirus vaccine for emergency use.

According to reports, a total of 950 healthy adults between the ages of 18 and 59 were recruited in the two domestic clinical trials of the vaccine, using a randomized, double-blind, and placebo-controlled trial protocol.

The results showed that no serious vaccine-related adverse events occurred.

Currently, the vaccine is undergoing international multi-center phase III clinical trials in Uzbekistan, Indonesia, Pakistan and Ecuador, and was approved for registration in Uzbekistan on March 1.

Recombinant protein subunit vaccines express and purify pathogen antigen proteins in engineered cells through genetic engineering, and then prepare them into vaccines.

Up to now, my country has 4 new coronavirus vaccines on the market conditionally, and one new coronavirus vaccine has been approved for emergency use.